Eli Lilly stock may look expensive, but that may not be the case in a few years as the business grows at a rapid pace.Berkshire Hathaway recently crossed the $1 trillion market cap, becoming the first non-tech stock to do so. While the stock has given back some gains in recent days and fallen below that threshold, it's still an incredible accomplishment nonetheless.But there's another non-tech stock which could be worth $1 trillion in the near future, and that's Eli Lilly (LLY -0.13%). The healthcare giant ...

Lilly could take a step that's positive for the stock and investors over the long term.Eli Lilly (LLY -0.13%) offers investors the same thing as many other big pharma companies: a certain level of security when it comes to revenue. Since people need their medicines regardless of the economic environment, these players generally are linked to some earnings stability and visibility. But Lilly has stood out from the crowd in recent quarters by also giving investors something that's generally seen more in techn ...

Eli Lilly and Company’s (LLY) stock has risen 21.1% in six months compared with an increase of 10.5% for the industry. The stock has also outperformed the sector as well as the S&P 500 as seen in the chart below.LLY Stock Outperforms Industry, Sector & S&P 500    Image Source: Zacks Investment ResearchLilly has seen unparalleled success with its GLP-1 drugs, Mounjaro and Zepbound. In the past couple of years, it has received approvals for several new drugs like Kisunla, Omvoh and Jaypirca and witnessed pipe ...

Core Insights - Eli Lilly is approaching a market capitalization of $830 billion and is expected to join the trillion-dollar club soon [2] - The healthcare industry, particularly in weight loss and Alzheimer's treatment, presents significant growth opportunities for Eli Lilly [3][5] Group 1: Market Opportunities - The global total addressable market (TAM) for GLP-1 medications is projected to grow to $145 billion by 2030, increasing fourfold from current estimates [4] - The TAM for Alzheimer's treatment is expected to reach nearly $31 billion by 2033, with a compound annual growth rate (CAGR) of 19% from 2024 to 2033 [5] Group 2: Competitive Landscape - Eli Lilly is positioned uniquely in the healthcare sector, with a focus on GLP-1 drugs and Alzheimer's treatment, while other pharmaceutical companies are also entering the weight loss market [4][5] - The company has received FDA approval for its Alzheimer's treatment, donanemab, enhancing its competitive edge in a fragmented market [5] Group 3: Strategic Initiatives - Eli Lilly has formed a strategic partnership with OpenAI to integrate generative AI into healthcare, aiming to improve clinical trial data processing and drug discovery [6] - The company continues to innovate and explore new areas beyond its current offerings, indicating a strong growth trajectory [8]

Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Over the past month, shares of this drugmaker have returned +0.2%, compared to the Zacks S&P 500 composite's +1.5% change. During this period, the Zacks Large Cap Pharmaceuticals industry, which Lilly falls in, has gained 1.5%. The key question now is: What could be the stock's future direction?Although media report ...

Eli Lilly and Company (LLY) announced that the FDA has granted approval to its IL-13 inhibitor Ebglyss (lebrikizumab) for treating moderate-to-severe atopic dermatitis, also called eczema. Ebglyss is approved for use in adults and children aged 12 and above who weigh at least 40 kgs and whose moderate-to-severe atopic dermatitis is not well controlled with topical prescription medicines.Ebglyss was approved in the European Union in 2023 and in Japan in January this year. The drug generated sales of $7.5 mil ...

EBGLYSS Approval and Efficacy - EBGLYSS, a targeted IL-13 inhibitor, has been approved by the FDA for the treatment of moderate-to-severe atopic dermatitis in adults and children aged 12 and older who weigh at least 40 kg [1] - Patients treated with EBGLYSS experienced significant skin clearance as early as four weeks and meaningful itch relief as early as two weeks [1] - In clinical trials, 38% of patients achieved clear or almost-clear skin at 16 weeks, compared to 12% with placebo, and 77% maintained these results at one year with monthly dosing [3] - 43% of patients experienced itch relief at 16 weeks, compared to 12% with placebo, and 85% maintained this relief at one year with monthly dosing [3] EBGLYSS Dosing and Administration - EBGLYSS is administered as a 250 mg/2 mL injection, with an initial dose of 500 mg at Week 0 and Week 2, followed by 250 mg every two weeks until Week 16, then a single monthly maintenance dose [2] - The drug can be used with or without topical corticosteroids [2] Clinical Trials and Study Results - The approval was based on results from the ADvocate 1, ADvocate 2, and ADhere studies, which included over 1,000 patients with moderate-to-severe eczema [3] - The primary endpoint was clear or almost-clear skin (IGA 0,1) at 16 weeks, with key secondary endpoints including Eczema Area and Severity Index (EASI) and Pruritus Numeric Rating Scale [6][7] Market and Commercialization - EBGLYSS was approved by the European Commission in 2023 and in Japan in January 2024, with additional markets expected later this year [5] - Lilly has exclusive rights for development and commercialization of EBGLYSS in the U.S. and the rest of the world outside Europe, while Almirall S.A. holds rights in Europe [5] Patient Impact and Market Potential - Nearly 16.5 million adults in the U.S. have eczema, with 6.6 million experiencing moderate-to-severe symptoms [3] - EBGLYSS offers a new first-line biologic treatment option for patients who do not respond well to topical therapies [3] Mechanism of Action - EBGLYSS is a monoclonal antibody that selectively targets and neutralizes IL-13, a cytokine implicated in the pathophysiology of eczema [15] - The drug binds to IL-13 at an area overlapping with the IL-4Rα subunit, preventing receptor complex formation and inhibiting IL-13 signaling [15] Future Developments - Further data results from the ADmirable and ADapt studies are expected to be shared in 2024 and early 2025 [15]

The drug giant's winning ways look set to continue for a while.It's hard not to admire what Eli Lilly (LLY 1.53%) has accomplished over the past five years. The drugmaker has been riding a wave of strong financial results and excellent regulatory progress to become the largest healthcare company by market capitalization. It's inching closer to a $1 trillion valuation -- and at the rate it has been going, don't be surprised if it hits that milestone within a year.However, despite the terrific gains Eli Lilly ...

Key TakeawaysEli Lilly is investing $1.8 billion to expand production in Ireland of its Alzheimer's treatment and weight-loss drugs.The company's Alzheimer's drug, Kisunla, was approved by the U.S. Food and Drug Administration last month.Eli Lilly has committed more than $20 billion to manufacturing investments in the U.S. and Europe since 2020. Eli Lilly (LLY) said Thursday it will spend $1.8 billion to expand production in Ireland of its popular diabetes and weight-loss drugs, as well as some active ingre ...

Large drug-maker stocks have witnessed a strong run this year, driven by positive pipeline news and regulatory approvals. The FDA has granted approval to 29 novel drugs this year. Innovation in the industry is at its peak, with spaces like weight loss/obesity, inflammation and Alzheimer’s disease attracting investor interest in 2024.Novel diabetes and obesity drugs of Eli Lilly (LLY) and Novo Nordisk have taken the pharma sector by storm with both Eli Lilly’s tirzepatide drugs (Mounjaro and Zepbound) and No ...